Illumina Inc. (NASDAQ:ILMN) – Stock analysts at First Analysis dropped their Q2 2017 earnings per share estimates for Illumina in a research note issued on Tuesday. First Analysis analyst T. Marshbanks now anticipates that the brokerage will post earnings per share of $0.88 for the quarter, down from their previous estimate of $0.95.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their target price on Illumina from $185.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 27th. Cantor Fitzgerald reiterated a “hold” rating and issued a $165.00 target price on shares of Illumina in a research report on Wednesday, July 27th. Janney Montgomery Scott lowered Illumina from a “neutral” rating to a “sell” rating and dropped their target price for the company from $155.00 to $125.00 in a research report on Tuesday. Mizuho upped their target price on Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Finally, Citigroup Inc. downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the company from $190.00 to $140.00 in a report on Tuesday. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $159.24.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Shares of Illumina (NASDAQ:ILMN) traded down 1.802% during midday trading on Wednesday, reaching $136.485. 2,291,632 shares of the company’s stock were exchanged. The stock has a market cap of $20.01 billion, a P/E ratio of 46.741 and a beta of 0.47. The company’s 50-day moving average is $174.01 and its 200-day moving average is $156.43. Illumina has a one year low of $127.10 and a one year high of $196.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business earned $600 million during the quarter, compared to analyst estimates of $31.91 million. During the same period last year, the firm posted $0.80 EPS. The company’s revenue was up 11.3% on a year-over-year basis.

A number of large investors have recently bought and sold shares of ILMN. Physicians Financial Services Inc. raised its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in Illumina during the second quarter worth about $112,000. Ropes Wealth Advisors LLC raised its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the stock in a transaction dated Friday, October 7th. The stock was sold at an average price of $184.36, for a total value of $110,616.00. Following the sale, the director now owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director A Blaine Bowman sold 5,000 shares of the stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $147.14, for a total value of $735,700.00. Following the completion of the sale, the director now directly owns 20,704 shares in the company, valued at approximately $3,046,386.56. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.